BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 2031502)

  • 1. A randomized trial of cyclophosphamide, doxorubicin, and prednisone versus cyclophosphamide, 5-fluorouracil, and prednisone in patients with metastatic breast cancer.
    Ahmann DL; Schaid DJ; Ingle JN; Bisel HF; Schutt AJ; Buckner JC; Long HJ; Rubin J
    Am J Clin Oncol; 1991 Jun; 14(3):179-83. PubMed ID: 2031502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy in advanced breast carcinoma. Comparison between doxorubicin-cyclophosphamide and cyclophosphamide-methotrexate-5-fluorouracil-vincristine-prednisone.
    Parvinen LM; Numminen S
    Acta Radiol Oncol; 1985; 24(5):391-4. PubMed ID: 3002135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase III clinical trial comparing the combination cyclophosphamide, adriamycin, cisplatin with cyclophosphamide, 5-fluorouracil, prednisone in patients with advanced breast cancer.
    Creagan ET; Green SJ; Ahmann DL; Ingle JN; Edmonson JH; Marschke RF
    J Clin Oncol; 1984 Nov; 2(11):1260-5. PubMed ID: 6387059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone.
    Pinnamaneni K; Yap HY; Buzdar AU; Distefano A; Blumenschein GR
    Cancer; 1984 May; 53(9):1841-4. PubMed ID: 6546706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281.
    Aisner J; Cirrincione C; Perloff M; Perry M; Budman D; Abrams J; Panasci L; Muss H; Citron M; Holland J
    J Clin Oncol; 1995 Jun; 13(6):1443-52. PubMed ID: 7751891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized clinical trial of CFP versus CMFP in women with metastatic breast cancer.
    Marschke RF; Ingle JN; Schaid DJ; Krook JE; Mailliard JA; Cullinan SA; Pfeifle DM; Votava HJ; Ebbert LP; Windschitl HE
    Cancer; 1989 May; 63(10):1931-7. PubMed ID: 2649221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternating versus sequential therapy in advanced breast cancer.
    Romero A; Rabinovich MG; Pérez JE; Macchiavelli M; Leone BA; Strauss E; Goldar D; Alvarez LA; Vallejo C
    Medicina (B Aires); 1987; 47(3):243-8. PubMed ID: 3326994
    [No Abstract]   [Full Text] [Related]  

  • 8. Fluorouracil, doxorubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide plus lonidamine for the treatment of advanced breast cancer: a multicentric randomized clinical study.
    Calabresi F; Di Lauro L; Marolla P; Curcio CG; Paoletti G; Calabró A; Giannarelli D; Ballatore P; Foggi CM; Di Palma M
    Semin Oncol; 1991 Apr; 18(2 Suppl 4):66-72. PubMed ID: 2031201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
    Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
    Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B.
    Aisner J; Weinberg V; Perloff M; Weiss R; Perry M; Korzun A; Ginsberg S; Holland JF
    J Clin Oncol; 1987 Oct; 5(10):1523-33. PubMed ID: 3655855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial to evaluate the addition of tamoxifen to cyclophosphamide, 5-fluorouracil, prednisone adjuvant therapy in premenopausal women with node-positive breast cancer.
    Ingle JN; Everson LK; Wieand HS; Cullinan SA; Wold LE; Hagen JB; Martin JK; Krook JE; Fitzgibbons RG; Foley JF
    Cancer; 1989 Apr; 63(7):1257-64. PubMed ID: 2646004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative, randomized trial of UFT and 5-fluorouracil in combination with cyclophosphamide and doxorubicin in the treatment of advanced breast cancer patients at The Philippines General Hospital.
    Villalon AH; De Guzman LM; Samson MC; Guancia AA; Fernando GY; Romana IB
    Oncology; 1997; 54 Suppl 1():2-6. PubMed ID: 8978577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer.
    Smalley RV; Lefante J; Bartolucci A; Carpenter J; Vogel C; Krauss S
    Breast Cancer Res Treat; 1983; 3(2):209-20. PubMed ID: 6688538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastatic breast cancer: higher versus low dose maintenance treatment when only a partial response or a no change status is obtained following doxorubicin induction treatment. An Eastern Cooperative Oncology Group study.
    Falkson G; Gelman RS; Glick J; Falkson CI; Harris J
    Ann Oncol; 1992 Nov; 3(9):768-70. PubMed ID: 1450067
    [No Abstract]   [Full Text] [Related]  

  • 15. Multiple drug intensification after cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) induction in metastatic breast cancer: a Southeastern Cancer Study Group phase II trial.
    Vogel CL; Raney M; Carpenter J
    Cancer Treat Rep; 1987 Dec; 71(12):1271-3. PubMed ID: 3690536
    [No Abstract]   [Full Text] [Related]  

  • 16. An evaluation of the effect of vincristine added to cyclophosphamide, 5-fluorouracil, methotrexate, and prednisone in advanced breast cancer.
    Segaloff A; Hankey BF; Carter AC; Escher GC; Ansfield FJ; Talley RW
    Breast Cancer Res Treat; 1985; 5(3):311-9. PubMed ID: 3896353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-Fluorouracil, adriamycin, cyclophosphamide (FAC) vs. 5-fluorouracil, epirubicin, cyclophosphamide (FEC) in metastatic breast cancer.
    Lopez M; Papaldo P; Di Lauro L; Vici P; Carpano S; Conti EM
    Oncology; 1989; 46(1):1-5. PubMed ID: 2915887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma.
    Bennett JM; Muss HB; Doroshow JH; Wolff S; Krementz ET; Cartwright K; Dukart G; Reisman A; Schoch I
    J Clin Oncol; 1988 Oct; 6(10):1611-20. PubMed ID: 3049953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of four-combination chemotherapy programs in metastatic breast cancer: comparison of multiple drug therapy with cytoxan, 5-FU and prednisone versus cytoxan and adriamycin, versus cytoxan, 5-FU and adriamycin, versus cytoxan, 5-FU and prednisone alternating with cytoxan and adriamycin.
    Nemoto T; Horton J; Simon R; Dao TL; Rosner D; Cunningham T; Sponzo R; Snyderman M
    Cancer; 1982 May; 49(10):1988-93. PubMed ID: 7074523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.